公开(公告)号：JP2012041349A

公开(公告)日：2012-03-01

申请号：JP2011202172

申请日：2011-09-15

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： SCHRIMPF MICHAEL R ,  TIETJE KARIN R ,  TOUPENCE RICHARD B ,  JI JIANGUO ,  BASHA ANWER ,  BUNNELLE WILLIAM H ,  DAANEN JEROME F ,  PACE JENNIFER M ,  SIPPY KEVIN B

IPC: C07D231/54 ,  C07D487/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: PROBLEM TO BE SOLVED: To provide a series of N-substituted diazabicyclic compound, a method for selectively controlling releasing of a synaptic transmission substance in mammals by using the compound, and a pharmaceutical composition including the compound.SOLUTION: The present invention provides a compound expressed by formula (I), a pharmaceutical composition of the compound, and use of the composition to control synaptic transmission in mammals (in a nicotinic acetylcholine receptor ligand). In formula (I), A is selected from a group consisting of CH2, CH2CH2, and the like; B is selected from a group consisting of CH2 and CH2CH2, however, when A is CH2CH2CH2, B is CH2; Y is selected from a group consisting of CH2 and CH2CH2; Z is selected from a group consisting of CH2 and CH2CH2, however, when Y is CH2CH2, Z is a covalent bond, and when Z is CH2CH2, Y is a covalent bond; and Rl is pyridine or the like.

Abstract translation: 待解决的问题：提供一系列N-取代的二氮杂双环化合物，通过使用该化合物选择性地控制哺乳动物突触传递物质的释放的方法和包含该化合物的药物组合物。 解决方案：本发明提供由式（I）表示的化合物，该化合物的药物组合物，以及该组合物用于控制哺乳动物（在烟碱乙酰胆碱受体配体）中突触传递的用途。 在式（I）中，A选自由CH 2，CH 2 CH 2等组成的组; B选自CH 2和CH 2 CH 2，但是当A是CH 2 CH 2 CH 2时，B是CH 2; Y选自CH 2和CH 2 CH 2; Z选自CH 2和CH 2 CH 2，但是当Y为CH 2 CH 2时，Z为共价键，当Z为CH 2 CH 2时，Y为共价键; 并且R 1是吡啶等。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：WO0181347A3

公开(公告)日：2002-01-31

申请号：PCT/US0113798

申请日：2001-04-27

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  TIETJE KARIN R ,  TOUPENCE RICHARD B ,  JI JIANGUO ,  BASHA ANWER ,  BUNNELLE WILLIAM H ,  DAANEN JEROME F ,  PACE JENNIFER M ,  SIPPY KEVIN B

IPC: C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  A61K31/395 ,  C07D471/08 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Compounds of formula (I), pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals (nicotinic acetylcholine receptor ligands).

Abstract translation: 式（I）的化合物，这些化合物的药物组合物，以及所述组合物用于控制哺乳动物（烟碱乙酰胆碱受体配体）中突触传递的用途。

公开(公告)号：WO0119817A3

公开(公告)日：2002-01-17

申请号：PCT/US0025444

申请日：2000-09-14

Applicant: ABBOTT LAB

Inventor： LIN NAN-HORNG ,  LI YIHONG ,  DRIZIN IRENE ,  KINCAID JOHN F ,  BASHA ANWER ,  DONG LIMING ,  HAKEEM AHMED A

IPC: A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K31/55 ,  A61P1/00 ,  A61P1/04 ,  A61P1/14 ,  A61P15/10 ,  A61P21/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/34 ,  C07D401/12 ,  C07D401/14 ,  C07D409/14 ,  A61K31/4427

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D409/14

Abstract: A series of 3-pyrrolidinyloxy-3'-pyridyl ether compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions including these compounds. Preferred compounds are 3-pyrrolidinylmethoxy-3'-(5'-and/or 6'-substituted) pyridyl ethers.

Abstract translation: 一系列3-吡咯烷氧基-3'-吡啶基醚化合物，使用这些化合物选择性控制哺乳动物中的神经递质释放的方法，以及包括这些化合物的药物组合物。 优选的化合物是3-吡咯烷基甲氧基-3' - （5'-和/或6'-取代的）吡啶基醚。

公开(公告)号：EP0667855A4

公开(公告)日：1996-02-21

申请号：EP94902209

申请日：1993-11-05

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BHATIA PRAMILA ,  BROOKS DEE W ,  CRAIG RICHARD A ,  RATAJCZYK JAMES D ,  STEWART ANDREW O

IPC: A61K31/17 ,  A61K31/38 ,  A61K31/381 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4433 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C273/18 ,  C07C275/24 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D333/22 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D417/04 ,  C07C275/20

CPC classification number: C07D405/06 ,  C07C275/64 ,  C07D213/61 ,  C07D277/28 ,  C07D307/52 ,  C07D333/20 ,  C07D409/06

公开(公告)号：MY145722A

公开(公告)日：2012-03-30

申请号：MYPI20055633

申请日：2001-04-26

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  TIETJE KARIN R ,  TOUPENCE RICHARD B ,  JI JIANGUO ,  BASHA ANWER ,  BUNNELLE WILLIAM H ,  DAANEN JEROME F ,  PACE JENNIFER MARY ,  SIPPY KEVIN B

IPC: A61P25/00 ,  C07D231/54 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  C07D471/04 ,  C07D487/04

Abstract: COMPOUNDS OF FORMULA I PHARMACEUTICAL COMPOSITIONS OF THESE COMPOUNDS, AND USE OF SAID COMPOSITIONS TO CONTROL SYNAPTIC TRANSMISSION IN MAMMALS.

公开(公告)号：SI1124804T1

公开(公告)日：2006-02-28

申请号：SI9930842

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: C07D237/00 ,  A61K31/00 ,  C07D405/00 ,  C07D409/00

公开(公告)号：BG64675B1

公开(公告)日：2005-11-30

申请号：BG10424100

申请日：2000-03-15

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL ,  LIU HUAQING ,  MCCARTY CATHERINE ,  PATEL MEENA ,  RHODE JEFFREY

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: The pyridazinon compounds are selective inhibitors of cyclooxygenase (COX), in particular of cyclooxygenase-2 (COX/2), COX-2 - inducible isoform which is related to the respective inflammation, as opposite to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important enzyme in many tissues, including the gastrointestinal tract and in the kidneys. The selectivity of the COX-2 compounds reduces to a minimum the unwanted side effects in the gastrointestinal tract and in the kidneys observed in the so-far knowm nonsteroid antiphlogistic medicaments.

公开(公告)号：AT302759T

公开(公告)日：2005-09-15

申请号：AT99953259

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：CA2538789A1

公开(公告)日：2005-03-31

申请号：CA2538789

申请日：2004-09-17

Applicant: ABBOTT LAB

Inventor： JI JIANGUO ,  SCHRIMPF MICHAEL R ,  NERSESIAN DIANA L ,  MORTELL KATHLEEN H ,  RYTHER KEITH B ,  PACE JENNIFER M ,  TIETJE KARIN R ,  BUNNELLE WILLIAM H ,  DART MICHAEL J ,  GALLAGHER MEGAN E ,  BASHA ANWER ,  LI TAO

IPC: C07D471/04 ,  A61K31/435 ,  A61P25/00 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4- (methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by .alpha.7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I ) and methods for using such compounds and compositions.

公开(公告)号：PL355418A1

公开(公告)日：2004-04-19

申请号：PL35541898

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).